Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventing CNS Recurrence in High-risk DLBCL
NCT07917624Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lenalidomidetucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07917624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917624.